Japan-based FUJIFILM Corporation has announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development ...
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the launch of Tetracycline-Enabl...
Vetter’s high-level performance further substantiates its dedicated performance in customer-critical services R...
The World Health Organization (WHO), the Republic of Korea and the WHO Academy have announced the establishment of a glo...
Moderna, Inc. and Thermo Fisher Scientific Inc. have announced a 15-year strategic collaboration agreement to enable ded...
US-based Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize develop...
US-based Avantor, Inc. has started construction on a distribution centre which will help expedite access to essential pr...
GenScript Biotech Corporation has announced the opening of a new facility for highly automated protein and gene pr...
New South Wales (NSW) will leverage its world-class cell and gene therapy expertise to establish Australia’s first...
South Korea-based Samsung Biologics has reached an agreement with Biogen for the buyout of Biogen's stake in the Sa...
Atara Biotherapeutics, Inc. has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies...
WuXi STA, a subsidiary of WuXi AppTec, has announced that its first parenteral formulation manufacturing line ...
GenScript ProBio, a global antibody and gene therapy contract development and manufacturing organization (CDMO), has ann...
Important milestone reached for the new site Additional filling capacities for early-stage clinical development Firs...
The Centre for Breakthrough Medicines (CBM), based in the US, has received $350 million in equity financing from South K...
The inauguration ceremony of Biosyngen joint projects and Biosyngen biological production base was held recently in ...
Novavax, Inc. and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, have announced the ...
Curocell, currently on PhaseⅠCAR-T Therapy clinical trial with CRC01 (anbalcabtagene autoleucel), has recently broken ...
